News and Trends 5 Jun 2015
Abivax launched an Euronext IPO to build up its anti-viral portfolio
Abivax has ended the paperwork and launched its IPO on Euronext Paris, where the biotech company plans to raise €43.6M. The clinical stage biotech is focused on developing anti-viral compounds and human vaccines. The French biotech want to insufflate the raised cash in its three developing products. Data from the two most advanced ones, ABX203 and ABX464, suggest that […]
